Agios Pharmaceuticals AGIO Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's short- and long-term operating lease liabilities?
- Agios Pharmaceuticals (AGIO) reported short- and long-term operating lease liabilities of -$4.46M in Q1 2026.
- How has Agios Pharmaceuticals's short- and long-term operating lease liabilities changed year-over-year?
- Agios Pharmaceuticals's short- and long-term operating lease liabilities decreased by 10.2% year-over-year, from -$4.05M to -$4.46M.
- What is the long-term trend for Agios Pharmaceuticals's short- and long-term operating lease liabilities?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's short- and long-term operating lease liabilities has grown at a 22.2% compound annual growth rate (CAGR), from -$7.53M to -$16.78M.